NF-κB activation in cancer: A challenge for ubiquitination- and proteasome-based therapeutic approach

Seminars in Cancer Biology

Volumn 13, Issue 1, 2003, Pages 15-28

  Amit, Sharon ^a   Ben Neriah, Yinon ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Cancer; E3; IKK; NF B; Proteasome; Ubiquitination

Indexed keywords

BETA CATENIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEOME; TRANSCRIPTION FACTOR; CTNNB1 PROTEIN, HUMAN; CYSTEINE PROTEINASE; CYTOSKELETON PROTEIN; MULTIENZYME COMPLEX; PROTEASOME; PROTEIN SERINE THREONINE KINASE; STEROID RECEPTOR; TRANSACTIVATOR PROTEIN; UBIQUITIN;

CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CARCINOGENICITY; HODGKIN DISEASE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN TARGETING; REVIEW; TUMOR CELL; FEMALE; HUMAN; MALE; METABOLISM; NEOPLASM; PROTEIN TERTIARY STRUCTURE;

BETA CATENIN; CYSTEINE ENDOPEPTIDASES; CYTOSKELETAL PROTEINS; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MULTIENZYME COMPLEXES; NEOPLASMS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, STEROID; TRANS-ACTIVATORS; UBIQUITINS;

EID: 0037328613     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00096-2     Document Type: Article

References (199)

1. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:1998;225-260.
2. Miyamoto S., Verma I.M. REl/NF-κB/IκB story. Adv. Cancer Res. 66:1995;255-292.
3. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-κB. Annu. Rev. Cell. Biol. 10:1994;405-455.
4. Barnes P.J., Karin M. Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1997;1066-1071.
5. Baeuerle P.A., Baichwal V.R. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol. 65:1997;111-137.
6. Baeuerle P.A., Baltimore D. NF-κB: ten years after. Cell. 87:1996;13-20.
7. Baldwin A.S. Jr. Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 107:2001;3-6.
8. Silverman N., Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15:2001;2321-2342.
9. Beg A.A., Sha W.C., Bronson R.T., Ghosh S., Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature. 376:1995;167-169.
10. Beg A.A., Baltimore D. An essential role for NF-κB in preventing TNF-α induced cell death. Science. 274:1996;782-784.
11. Weih F., Carrasco D., Durham S.K., Barton D.S., Rizzo C.A., Ryseck R.P.et al. Multi-organ inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell. 80:1995;331-340.
12. Gerondakis S., Grossmann M., Nakamura Y., Pohl T., Grumont R. Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene. 18:1999;6888-6895.
13. Attar R.M., Caamano J., Carrasco D., Iotsova V., Ishikawa H., Ryseck R.P.et al. Genetic approaches to study Rel/NF-kappa B/I kappa B function in mice. Semin. Cancer Biol. 8:1997;93-101.
14. Li Q., Van Antwerp D., Mercurio F., Lee K.-F., Verma I.M. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science. 284:1999;321-325.
15. Makris C., Godfrey V.L., Krahn-Senftleben G., Takahashi T., Roberts J.L., Schwarz T.et al. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell. 5:2000;969-979.
16. Beg A.A., Sha W.C., Bronson R.T., Baltimore D. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Dev. 9:1995;2736-2746.
17. Mercurio F., Manning A.M. NF-kappaB as a primary regulator of the stress response. Oncogene. 18:1999;6163-6171.
18. Arch R.H., Gedrich R.W., Thompson C.B. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev. 12:1998;2821-2830.
19. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18:2000;621-663.
20. Delhase M., Karin M. The IκB kinase: a master regulator of NF-κB innate immunity and epidermal differentiation. In: Cold Spring Harbor Symposia on Quantitative Biology. 64:1999;491-503.
21. Rothwarf D.M., Zandi E., Natoli G., Karin M. IKKγ is an essential regulatory subunit of the IκB kinase complex. Nature. 395:1998;297-300.
22. Ling L., Cao Z., Goeddel D.V. NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2791-2797.
23. Delhase M., Hayakawa M., Chen Y., Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science. 284:1999;309-313.
24. Deng L., Wang C., Spencer E., Yang L., Braun A., You J.et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 103:2000;351-361.
25. Hofmann R.M., Pickart C.M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell. 96:1999;645-653.
26. Whiteside S.T., Israël A. I kappa B proteins: structure, function and regulation. Semin. Cancer Biol. 8:1997;75-82.
27. Alkalay I., Yaron A., Hatzubai A., Orian A., Ciechanover A., Ben-Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF- kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 92:1995;10599-10603.
28. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., Baeuerle P.A. Phosphorylation of human IκB on serines 32 and 36 controls IκB proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14:1995;2876-2883.
29. Baldi L., Brown K., Franzoso G., Siebenlist U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J. Biol. Chem. 271:1996;376-379.
30. Yaron A., Hatzubai A., Davis M., Lavon I., Amit S., Manning A.M.et al. Identification of the receptor component of the IκBα-ubiquitin ligase. Nature. 396:1998;590-594.
31. Spencer E., Jiang J., Chen Z.J. Singal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev. 13:1999;284-294.
32. Kroll M., Margottin F., Kohl A., Renard P., Durand H., Concordet J.P.et al. Inducible degradation of IkappaBalpha by the proteasome requires interaction with the F-box protein h-betaTrCP. J. Biol. Chem. 274:1999;7941-7945.
33. Hatakeyama S., Kitagawa M., Nakayama K., Shirane M., Matsumoto M., Hattori K.et al. Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3859-3863.
34. Deshaies R.J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell. Dev. Biol. 15:1999;435-467.
35. Ohta T., Michel J.J., Schottelius A.J., Xiong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell. 3:1999;535-541.
36. Yaron A., Gonen H., Alkalay I., Hatzubai A., Jung S., Beyth S.et al. Inhibition of NF-κB cellular function via specific targeting of the IκB-ubiquitin ligase. EMBO J. 16:1997;6486-6494.
37. Hart M., Concordet J.P., Lassot I., Albert I., del los Santos R., Durand H.et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 9:1999;207-210.
38. Margottin F., Bour S.P., Durand H., Selig L., Benichou S., Richard V.et al. A novel human WD protein, h-beta TrCP, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell. 1:1998;565-574.
39. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., Harper J.W. The SCF β-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 13:1999;270-283.
40. Polakis P. Wnt signaling and cancer. Genes Dev. 14:2000;1837-1851.
41. Hattori K., Hatakeyama S., Shirane M., Matsumoto M., Nakayama K. Molecular dissection of the interactions among IkappaBalpha, FWD1, and Skp1 required for ubiquitin-mediated proteolysis of IkappaBalpha. J. Biol. Chem. 274:1999;29641-29647.
42. Lin R.T., Beauparlant P., Makris C., Meloche S., Hiscott J. Phosphorylation of I-kappa-B-alpha in the C-terminal pest domain by casein kinase Iu affects intrinsic protein stability. Mol. Cell. Biol. 16:1996;1401-1409.
43. McKinsey T.A., Chu Z.L., Ballard D.W. Phosphorylation of the PEST domain of IkappaBbeta regulates the function of NF-kappaB/IkappaBbeta complexes. J. Biol. Chem. 272:1997;22377-22380.
44. Kitamura H., Kanehira K., Okita K., Morimatsu M., Saito M. MAIL, a novel nuclear I kappa B protein that potentiates LPS-induced IL-6 production. FEBS Lett. 485:2000;53-56.
45. Yamazaki S., Muta T., Takeshige K. A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. J. Biol. Chem. 276:2001;27657-27662.
46. Fiorini E., Schmitz I., Marissen W.E., Osborn S.L., Touma M., Sasada T.et al. Peptide-induced negative selection of thymocytes activates transcription of an NF-kappaB inhibitor. Mol. Cell. 9:2002;637-648.
47. Baldwin A.S. The NF-κB and IκB Proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-681.
48. Tam W.F., Sen R. IkappaB family members function by different mechanisms. J. Biol. Chem. 276:2001;7701-7704.
49. Turpin P., Hay R.T., Dargemont C. Characterization of IkappaBalpha nuclear import pathway. J. Biol. Chem. 274:1999;6804-6812.
50. Malek S., Chen Y., Huxford T., Ghosh G. Ikappa Bbeta, but not Ikappa Balpha, functions as a classical cytoplasmic inhibitor of NF-kappa B dimers by masking both NF-kappa B nuclear localization sequences in resting cells. J. Biol. Chem. 276:2001;45225-45235.
51. Johnson C., Van Antwerp D., Hope T.J. An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IkappaBalpha. EMBO J. 18:1999;6682-6693.
52. Davis M., Hatzubai A., Andersen J.S., Ben-Shushan E., Fisher G.Z., Yaron A.et al. Pseudosubstrate regulation of the SCF(beta-TrCP) ubiquitin ligase by hnRNP-U. Genes Dev. 16:2002;439-451.
53. Zhong H., May M.J., Jimi E., Ghosh S. The phosphorylation status of nuclear NF-kappaB determines its association with CBP/p300 or HDAC-1. Mol. Cell. 9:2002;625-636.
54. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 293:2001;1653-1657.
55. Willert K., Nusse R. Beta-catenin: a key mediator of Wnt signaling. Curr. Opin. Genet. Dev. 8:1998;95-102.
56. Wodarz A., Nusse R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell. Dev. Biol. 14:1998;59-88.
57. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science. 287:2000;1606-1609.
58. Hinoi T., Yamamoto H., Kishida M., Takada S., Kishida S., Kikuchi A. Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. J. Biol. Chem. 275:2000;34399-34406.
59. Hart M.J., de los Santos R., Albert I.N., Rubinfeld B., Polakis P. Downregulation of beta-catenin by human axin and its association with the APC tumor suppressor. Curr. Biol. 8:1998;573-581.
60. Amit S., Hatzubai A., Birman Y., Andersen J.A., Ben-Shushan E., Mann M.et al. Axin-mediated CKI-phosphorylation of beta-catenin at Ser45: a molecular switch for the Wnt pathway. Genes Dev. 16:2002;1066-1076.
61. Liu C., Li Y., Semenov M., Han C., Baeg G.-H., Tan Y.et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 108:2002;837-847.
62. Schwarz-Romond T, Asbrand C, Bakkers J, Kuhl M, Schaeffer H-J, Huelsken J, Behrens J, Hammerschmidt M, Birchmeier W. The ankyrin repeat protein Diversin recruits Casein kinase Iε to the β-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. Genes Dev, in press.
63. Nusse R. WNT targets. Repression and activation. Trends Genet. 15:1999;1-3.
64. Roelink H., Wagenaar E., Lopes da Silva S., Nusse R. Wnt-3, a gene activated by proviral insertion in mouse mammary tumors, is homologous to int-1/Wnt-1 and is normally expressed in mouse embryos and adult brain. Proc. Natl. Acad. Sci. U.S.A. 87:1990;4519-4523.
65. Polakis P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 9:1999;15-21.
66. Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C., Murphy L.M., Nagorney D.M., Burgart L.J., Roche P.C., Smith D.I., Ross J.A., Liu W. Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 21g:2002;4863-4871.
67. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B.et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1997;1787-1790.
68. Wong C.M., Fan S.T., Ng I.O. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 92:2001;136-145.
69. Kinzler K.W., Nilbert M.C., Su L.K., Vogelstein B., Bryan T.M., Levy D.B.et al. Identification of FAP locus genes from chromosome 5q21. Science. 253:1991;661-665.
70. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H.et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 66:1991;589-600.
71. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim. Biophys. Acta. 1332:1997;F127-F147.
72. Clevers H. Axin and hepatocellular carcinomas. Nat. Genet. 24:2000;206-208.
73. Dahmen R.P., Koch A., Denkhaus D., Tonn J.C., Sorensen N., Berthold F.et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res. 61:2001;7039-7043.
74. Webster M.T., Rozycka M., Sara E., Davis E., Smalley M., Young N.et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer. 28:2000;443-453.
75. Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1998;1130-1134.
76. Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L.et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell. 7:2001;927-936.
77. Matsuzawa S.I., Reed J.C. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell. 7:2001;915-926.
78. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107:2001;241-246.
79. Luque I., Gélinas C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin. Cancer Biol. 8:1997;103-111.
80. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 18:1999;6938-6947.
81. Gilmore T.D., Koedood M., Piffat K.A., White D.W. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene. 13:1996;1367-1378.
82. Gilmore T.D., Cormier C., Jean-Jacques J., Gapuzan M.E. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. In: Oncogene. 20:2002;7098-7103.
83. Finco T.S., Westwick J.K., Norris J.L., Beg A.A., Der C.J., Baldwin A.S. Jr. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272:1997;24113-24116.
84. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 12:1998;968-981.
85. Whitehead I.P., Lambert Q.T., Glaven J.A., Abe K., Rossman K.L., Mahon G.M.et al. Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation. Mol. Cell. Biol. 19:1999;7759-7770.
86. Mosialos G. The role of Rel/NF-kappa B proteins in viral oncogenesis and the regulation of viral transcription. Semin. Cancer Biol. 8:1997;121-129.
87. Staudt L.M. The molecular and cellular origins of Hodgkin's disease. J. Exp. Med. 191:2000;207-212.
88. Cao Y., Bonizzi G., Seagroves T.N., Greten F.R., Johnson R., Schmidt E.V.et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 107:2001;763-775.
89. Mitin N., Kudla A.J., Konieczny S.F., Taparowsky E.J. Differential effects of Ras signaling through NFkappaB on skeletal myogenesis. Oncogene. 20:2001;1276-1286.
90. Hinz M., Krappmann D., Eichten A., Heder A., Scheidereit C., Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19:1999;2690-2698.
91. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:1999;5785-5799.
92. Romashkova J.A., Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 401:1999;86-90.
93. Toth C.R., Hostutler R.F., Baldwin A.S. Jr., Bender T.P. Members of the nuclear factor kappa B family transactivate the murine c-myb gene. J. Biol. Chem. 270:1995;7661-7671.
94. Duyao M.P., Kessler D.J., Spicer D.B., Bartholomew C., Cleveland J.L., Siekevitz M.et al. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J. Biol. Chem. 267:1992;16288-16291.
95. Perkins N.D., Felzien L.K., Betts J.C., Leung K., Beach D.H., Nabel G.J. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science. 275:1997;523-527.
96. Wolff B., Naumann M. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB. Oncogene. 18:1999;2663-2666.
97. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18:1999;6853-6866.
98. Devalaraja M.N., Wang D.Z., Ballard D.W., Richmond A. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res. 59:1999;1372-1377.
99. Wu M.X., Ao Z., Prasad K.V., Wu R., Schlossman S.F. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science. 281:1998;998-1001.
100. Wang D., Baldwin A.S. Jr. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273:1998;29411-29416.
101. Mayo M.W., Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta. 1470:2000;M55-M62.
102. Liu Z.-G., Baskaran R., Lea-Chou E.T., Wood L.D., Chen Y., Karin M.et al. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature. 384:1996;273-276.
103. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 274:1996;787-789.
104. Sumitomo M., Tachibana M., Nakashima J., Murai M., Miyajima A., Kimura F.et al. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J. Urol. 161:1999;674-679.
105. Mayo W.M., Wang C., Cogswell P.C., Rogers-Graham K.S., Lower S.W., Der C.J.et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science. 278:1997;1812-1815.
106. Stehlik C., de Martin R., Kumabashiri I., Schmid J.A., Binder B.R., Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 188:1998;211-216.
107. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19:1999;5923-5929.
108. Zong W.X., Edelstein L.C., Chen C., Bash J., Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 13:1999;382-387.
109. Grumont R.J., Rourke I.J., Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev. 13:1999;400-411.
110. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L.et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 13:1999;2207-2217.
111. Thisse C., Perrin-Schmitt F., Stoetzel C., Thisse B. Sequence-specific transactivation of the Drosophila twist gene by the dorsal gene product. Cell. 65:1991;1191-1201.
112. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 289:2000;2363-2366.
113. Shao J., Fujiwara T., Kadowaki Y., Fukazawa T., Waku T., Itoshima T.et al. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene. 19:2000;726-736.
114. Webster G.A., Perkins N.D. Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19:1999;3485-3495.
115. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature. 404:2000;892-897.
116. Schmitt C.A., Lowe S.W. Apoptosis and therapy. J. Pathol. 187:1999;127-137.
117. Kastan M.B. Molecular determinants of sensitivity to antitumor agents. Biochim. Biophys. Acta. 1424:1999;R37-R42.
118. Li N., Karin M. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13012-13017.
119. Wang C.-Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 274:1996;784-787.
120. Cusack J.C. Jr., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J.et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:2001;3535-3540.
121. Jeremias I., Kupatt C., Baumann B., Herr I., Wirth T., Debatin K.M. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood. 91:1998;4624-4631.
122. Masdehors P., Omura S., Merle-Beral H., Mentz F., Cosset J.M., Dumont J.et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 105:1999;752-757.
123. Sovak M.A., Arsura M., Zanieski G., Kavanagh K.T., Sonenshein G.E. The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression. Cell Growth Differ. 10:1999;537-544.
124. Wang C.Y., Cusack J.C. Jr., Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5:1999;412-417.
125. Zhou G., Kuo M.T. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem. 272:1997;15174-15183.
126. Um J.H., Kang C.D., Lee B.G., Kim D.W., Chung B.S., Kim S.H. Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene. 20:2001;6048-6056.
127. Fox S.B., Gasparini G., Harris A.L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2:2001;278-289.
128. Chilov D., Kukk E., Taira S., Jeltsch M., Kaukonen J., Palotie A.et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J. Biol. Chem. 272:1997;25176-25183.
129. Giatromanolaki A., Harris A.L. Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res. 21:2001;4317-4324.
130. Geller D.A., Nussler A.K., Di Silvio M., Lowenstein C.J., Shapiro R.A., Wang S.C.et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 90:1993;522-526.
131. Yamamoto K., Arakawa T., Ueda N., Yamamoto S. Transcriptional roles of nuclear factor κ B and nuclear factor-interleukin 6 in the tumor necrosis-α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270:1995;31315-31320.
132. Takeshita H., Yoshizaki T., Miller W.E., Sato H., Furukawa M., Pagano J.S.et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J. Virol. 73:1999;5548-5555.
133. Bond M., Baker A.H., Newby A.C. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem. Biophys. Res. Commun. 264:1999;561-567.
134. Andela V.B., Schwarz E.M., Puzas J.E., O'Keefe R.J., Rosier R.N. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res. 60:2000;6557-6562.
135. Bhat-Nakshatri P., Newton T.R., Goulet R. Jr., Nakshatri H. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6971-6976.
136. Johnson J.P. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 18:1999;345-357.
137. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer. 1:2001;34-45.
138. Sommer S., Fuqua S.A. Estrogen receptor and breast cancer. Semin. Cancer Biol. 11:2001;339-352.
139. Geymayer S., Doppler W. Activation of NF-kappaB p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated beta-casein gene expression. FASEB J. 14:2000;1159-1170.
140. Clarkson R.W., Heeley J.L., Chapman R., Aillet F., Hay R.T., Wyllie A.et al. NF-kappaB inhibits apoptosis in murine mammary epithelia. J. Biol. Chem. 275:2000;12737-12742.
141. Segev D.L., Ha T.U., Tran T.T., Kenneally M., Harkin P., Jung M.et al. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J. Biol. Chem. 275:2000;28371-28379.
142. Brantley D.M., Chen C.L., Muraoka R.S., Bushdid P.B., Bradberry J.L., Kittrell F.et al. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell. 12:2001;1445-1455.
143. Joyce D., Albanese C., Steer J., Fu M., Bouzahzah B., Pestell R.G. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 12:2001;73-90.
144. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 411:2001;1017-1021.
145. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M.et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100:1997;2952-2960.
146. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J. Jr., Sledge G.W. Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17:1997;3629-3639.
147. Evans M.J., Eckert A., Lai K., Adelman S.J., Harnish D.C. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ. Res. 89:2001;823-830.
148. Biswas D.K., Cruz A.P., Gansberger E., Pardee A.B. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 97:2000;8542-8547.
149. Romieu-Mourez R., Landesman-Bollag E., Seldin D.C., Traish A.M., Mercurio F., Sonenshein G.E. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res. 61:2001;3810-3818.
150. Zhou B.P., Hu M.C., Miller S.A., Yu Z., Xia W., Lin S.Y.et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 275:2000;8027-8031.
151. Biswas D.K., Dai S.C., Cruz A., Weiser B., Graner E., Pardee A.B. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10386-10391.
152. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2:2000;252-257.
153. Huang S., Pettaway C.A., Uehara H., Bucana C.D., Fidler I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 20:2001;4188-4197.
154. Lindholm P.F., Bub J., Kaul S., Shidham V.B., Kajdacsy-Balla A. The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin. Exp. Metastasis. 18:2000;471-479.
155. Palayoor S.T., Youmell M.Y., Calderwood S.K., Coleman C.N., Price B.D. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 18:1999;7389-7394.
156. Pajonk F., Pajonk K., McBride W.H. Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J. Natl. Cancer Inst. 91:1999;1956-1960.
157. Kimura K., Bowen C., Spiegel S., Gelmann E.P. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res. 59:1999;1606-1614.
158. Kimura K., Markowski M., Bowen C., Gelmann E.P. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 61:2001;5611-5618.
159. Muenchen H.J., Lin D.L., Walsh M.A., Keller E.T., Pienta K.J. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor" Clin. Cancer Res. 6:2000;1969-1977.
160. Supakar P.C., Jung M.H., Song C.S., Chatterjee B., Roy A.K. Nuclear factor kappa B functions as a negative regulator for the rat androgen receptor gene and NF-kappa B activity increases during the age-dependent desensitization of the liver. J. Biol. Chem. 270:1995;837-842.
161. Ogretmen B., Safa A.R. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry. 38:1999;2189-2199.
162. Dong G., Chen Z., Kato T., Van Waes C. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res. 59:1999;3495-3504.
163. Huang S., DeGuzman A., Bucana C.D., Fidler I.J. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin. Cancer Res. 6:2000;2573-2581.
164. Duffey D.C., Chen Z., Dong G., Ondrey F.G., Wolf J.S., Brown K.et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 59:1999;3468-3474.
165. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W.et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100:1997;2961-2969.
166. Gruss H.J., Pinto A., Duyster J., Poppema S., Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol. Today. 18:1997;156-163.
167. Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dorken B., Scheidereit C. Molecular mechanisms of constitutive NF-kappa B/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 18:1999;943-953.
168. Wood K.M., Roff M., Hay R.T. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene. 16:1998;2131-2139.
169. Cabannes E., Khan G., Aillet F., Jarrett R.F., Hay R.T. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 18:1999;3063-3070.
170. Jungnickel B., Staratschek-Jox A., Brauninger A., Spieker T., Wolf J., Diehl V.et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J. Exp. Med. 191:2000;395-402.
171. Gruss H.J., Brach M.A., Drexler H.G., Bonifer R., Mertelsmann R.H., Herrmann F. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 52:1992;3353-3360.
172. Hsu S.M., Hsu P.L. Autocrine and paracrine functions of cytokines in malignant lymphomas. Biomed. Pharmacother. 48:1994;433-444.
173. Chan W.C. The Reed-Sternberg cell in classical Hodgkin's disease. Hematol. Oncol. 19:2001;1-17.
174. Carbone A., Gloghini A., Gattei V., Aldinucci D., Degan M., De Paoli P.et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood. 85:1995;780-789.
175. Gruss H.J., Ulrich D., Dower S.K., Herrmann F., Brach M.A. Activation
176. Epinat J.C., Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene. 18:1999;6896-6909.
177. Palayoor S.T., Bump E.A., Calderwood S.K., Bartol S., Coleman C.N. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin. Cancer Res. 4:1998;763-771.
178. Ryan C.W., Stadler W.M., Vogelzang N.J. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin. Oncol. 28:2001;56-61.
179. Shacter E, Weitzman, SA. Chronic inflammation and cancer. Oncology (Huntingt) 2002;16:217-26, 229 [discussion 230-12].
180. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194:2001;1861-1874.
181. Rothe M., Xiong J., Shu H.-B., Williamson K., Goddard A., Goeddel D.V. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc. Natl. Acad. Sci. U.S.A. 93:1996;8241-8246.
182. Sun Z., Arendt C.W., Ellmeier W., Schaeffer E.M., Sunshine M.J., Gandhi L.et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature. 404:2000;402-407.
183. Pierce J.W., Read M.A., Ding H., Luscinskas F.W., Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 156:1996;3961-3969.
184. Kopp E., Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 265:1994;956-959.
185. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 396:1998;77-80.
186. Tsai S.H., Liang Y.C., Lin-Shiau S.Y., Lin J.K. Suppression of TNFalpha-mediated NFkappaB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells. J. Cell. Biochem. 74:1999;606-615.
187. Plummer S.M., Holloway K.A., Manson M.M., Munks R.J., Kaptein A., Farrow S.et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 18:1999;6013-6020.
188. Li N., Karin M. Is NF-κB the sensor of oxidative stress? FASEB J. 13:1999;1137-1143.
189. Lin Y.-C., Brown K., Siebenlist U. Activation of NF-κB requires proteolysis of the inhibitor IκB: signal-induced phosphorylation of IκB alone does not release active NF-κB. Proc. Natl. Acad. Sci. U.S.A. 92:1995;3003-3009.
190. Kawamura I., Morishita R., Tsujimoto S., Manda T., Tomoi M., Tomita N.et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene. Ther. 8:2001;905-912.
191. Tomita T., Takeuchi E., Tomita N., Morishita R., Kaneko M., Yamamoto K.et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 42:1999;2532-2542.
192. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8:2002;S49-S54.
193. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28:2001;613-619.
194. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 277:2002;16639-16647.
195. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N.et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
196. Fuchs S.Y., Chen A., Xiong Y., Pan Z.Q., Ronai Z. HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene. 18:1999;2039-2046.
197. Spiegelman V.S., Slaga T.J., Pagano M., Minamoto T., Ronai Z., Fuchs S.Y. Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol. Cell. 5:2000;877-882.
198. Spiegelman V.S., Tang W., Katoh M., Slaga T.J., Fuchs S.Y. Inhibition of HOS expression and activities by Wnt pathway. Oncogene. 21:2002;856-860.
199. Lavon I., Goldberg I., Amit S., Landsman L., Jung S., Tsuberi B.Z.et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat. Med. 6:2000;573-577.